Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Ocuphire Pharma Inc (OCUP)
Ocuphire Pharma Inc (OCUP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 57,274
  • Shares Outstanding, K 22,638
  • Annual Sales, $ 39,850 K
  • Annual Income, $ 17,890 K
  • 60-Month Beta 0.36
  • Price/Sales 0.96
  • Price/Cash Flow 2.95
  • Price/Book 1.06
Trade OCUP with:

Options Overview Details

View History
  • Implied Volatility 225.05% ( +101.74%)
  • Historical Volatility 41.10%
  • IV Percentile 95%
  • IV Rank 44.52%
  • IV High 482.16% on 01/23/24
  • IV Low 18.72% on 11/16/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 10
  • Volume Avg (30-Day) 81
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 3,113
  • Open Int (30-Day) 3,349

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.07
  • Number of Estimates 1
  • High Estimate -0.07
  • Low Estimate -0.07
  • Prior Year 1.58
  • Growth Rate Est. (year over year) -104.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.34 +8.12%
on 02/21/24
2.77 -8.66%
on 02/12/24
-0.20 (-7.33%)
since 02/01/24
3-Month
2.34 +8.12%
on 02/21/24
3.40 -25.58%
on 01/10/24
-0.46 (-15.38%)
since 12/01/23
52-Week
2.34 +8.12%
on 02/21/24
6.60 -61.67%
on 05/11/23
-0.95 (-27.30%)
since 03/01/23

Most Recent Stories

More News
Reata (RETA) Q1 Earnings Miss, Stock Dips on Pipeline Updates

Reata (RETA) incurs wider-than-expected loss in the first quarter. The company discontinues the development of bardoxolone methyl for diabetic kidney disease.

RETA : 172.36 (+0.02%)
RCUS : 19.10 (-0.16%)
ALLO : 4.94 (+0.61%)
OCUP : 2.53 (-0.20%)
TEVA Q1 Earnings Miss Estimates, Sales Beat, Stock Declines

TEVA reports mixed Q1 results, missing earnings estimates but beating the same for revenues. Stock falls.

TEVA : 13.50 (+2.66%)
RCUS : 19.10 (-0.16%)
ALLO : 4.94 (+0.61%)
OCUP : 2.53 (-0.20%)
Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Grow

Amicus (FOLD) incurs wider-than-expected loss in the first quarter. Revenues, however, beat estimates. The company reiterates its 2023 guidance.

FOLD : 13.29 (+3.67%)
RCUS : 19.10 (-0.16%)
ALLO : 4.94 (+0.61%)
OCUP : 2.53 (-0.20%)
Halozyme (HALO) Q1 Earnings Disappoint, Revenues Rise Y/Y

Halozyme (HALO) first-quarter earnings and revenues miss estimates. The company reiterates its guidance for 2023.

RHHBY : 33.0800 (+1.07%)
JNJ : 162.12 (+0.46%)
HALO : 41.11 (+3.27%)
OCUP : 2.53 (-0.20%)
Emergent (EBS) Q1 Earnings Miss Estimates, Revenues Beat

Emergent (EBS) reports wider-than-expected first-quarter loss. The company updates its 2023 guidance for selected categories.

AZN : 64.60 (+0.69%)
JNJ : 162.12 (+0.46%)
EBS : 3.39 (+4.95%)
OCUP : 2.53 (-0.20%)
CRISPR Therapeutics (CRSP) Q1 Earnings and Revenues Beat

CRISPR Therapeutics (CRSP) provides updates for its gene therapy candidates.

VRTX : 432.76 (+2.86%)
CRSP : 83.75 (-0.56%)
ALLO : 4.94 (+0.61%)
OCUP : 2.53 (-0.20%)
Intra-Cellular (ITCI) Q1 Earnings Top, Caplyta Volume Rises

Intra-Cellular (ITCI) first-quarter earnings and revenues beat estimates. The company reiterates its previously issued guidance for 2023.

ITCI : 71.49 (+2.83%)
RCUS : 19.10 (-0.16%)
ALLO : 4.94 (+0.61%)
OCUP : 2.53 (-0.20%)
Recent Price Trend in Ocuphire Pharma, Inc. (OCUP) is Your Friend, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Ocuphire Pharma, Inc. (OCUP) could be a great choice. It is one of the several stocks that passed through our "Recent...

OCUP : 2.53 (-0.20%)
Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Rise Y/Y

Puma Biotechnology (PBYI) earnings and sales beat estimates in Q1. Stock rises in after-hours.

PBYI : 5.89 (-5.31%)
RCUS : 19.10 (-0.16%)
ALLO : 4.94 (+0.61%)
OCUP : 2.53 (-0.20%)
Ironwood (IRWD) Q1 Earnings Beat Estimates, Linzess Volume Up

Ironwood (IRWD) reports better-than-expected results, wherein both earnings and revenues beat estimates. The strong momentum of Linzess continues with 10% growth in prescription demand.

AZN : 64.60 (+0.69%)
IRWD : 9.06 (-3.87%)
ABBV : 178.91 (+1.62%)
OCUP : 2.53 (-0.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ocuphire Pharma Inc. is a clinical-stage ophthalmic biopharmaceutical company. It is focused on developing and commercializing therapies for the treatment of several eye disorders. The company's product pipeline includes Nyxol Eye Drops(R) and APX3330. Ocuphire Pharma Inc., formerly known as Rexahn Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point 2.74
2nd Resistance Point 2.66
1st Resistance Point 2.59
Last Price 2.53
1st Support Level 2.44
2nd Support Level 2.36
3rd Support Level 2.29

See More

52-Week High 6.60
Fibonacci 61.8% 4.97
Fibonacci 50% 4.47
Fibonacci 38.2% 3.97
Last Price 2.53
52-Week Low 2.34

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar